Lilly stops testing of experimental schizophrenia drug
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
Health Care & Life Sciences
Articles
Departing CEO Braly due to get $15M exit package
WellPoint Inc. is expected to give about $15 million in cash, stock and benefits to former CEO Angela Braly on her way out the door, based on the terms of a separation agreement filed by the company Wednesday morning. And the payout could be even more lucrative based on the company’s future stock price.
WellPoint launches search for new CEO after Braly resignation
Investors are looking for a CEO who can right the Indianapolis-based company’s financial performance and integrate WellPoint’s recent deals to buy Medicaid insurer Amerigroup Corp. and vision company 1-800-Contacts Inc.
Salmonella at Indiana farm matches outbreak strain
A southwestern Indiana cantaloupe farm is the source of at least some of the salmonella responsible for an outbreak that sickened people in 21 states and killed two Kentucky residents, the Food and Drug Administration said Tuesday.
Braly’s departure occurred sooner than many expected
Even though CEO Angela Braly was facing withering criticism, analysts thought WellPoint would be reluctant to change CEOs while its $4.9 billion acquisition of Amerigroup Corp. was pending.
Records for 55,000 patients stolen from oncology group
The Cancer Care Group in Indianapolis said a laptop computer bag containing private information on as many as 55,000 patients has been stolen.
Candidate Gregg ‘leaning’ to hybrid health exchange
Democratic gubernatorial candidate John Gregg says he likely would support a hybrid health insurance exchange for Hoosiers if elected in November.
Does Lilly have enough on Alzheimer’s drug?
After Eli Lilly and Co. found a “glimmer of hope” in its test of its experimental Alzheimer’s drug, doctors and stock analysts generally concluded the company needs to conduct another long clinical trial to prove the drug’s effect. But one stock analyst thinks Lilly already has what it needs to ask for approval for its drug.
Subsidies might hang in the balance of state’s exchange decision
There’s more than political philosophy at stake as Indiana’s candidates for governor wrestle over whether the state should start its own health insurance exchange. There’s potentially a lot of money for low- and moderate-income Hoosiers at stake, too.
Lilly’s Alzheimer’s finding triggers investor hope, doctor caution
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
Boneham supports hybrid health exchange for state
The Libertarian candidate for governor said he initially favored a state-run exchange to administer the federal health care law, but chose a joint venture with the federal government after meeting with the governor's staff.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
$100M IU neuroscience center set to open
A $100 million neuroscience center Indiana University officials say will offer a "one stop shop" for patients recovering from head and spinal injuries, strokes and other medical conditions is days away from opening its doors in Indianapolis.
Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
WellPoint CEO’s critics suggesting replacements
Another plea for the ouster of WellPoint CEO Angela Braly is spurring discussions among investors and analysts about a replacement. Top suggestions include James G. Carlson, the chief of Amerigroup Corp., and David B. Snow Jr., the former chief of Medco Health Solutions Inc.
Lilly’s Alzheimer’s drug trials show mixed results
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Big WellPoint investor Royal Capital calls for CEO’s ouster
Royal Capital Management LLC is calling for the ouster of WellPoint Inc. CEO Angela Braly in a letter to the health insurer, saying she has “failed miserably.”
Cutting bills fuels growth of Health Systems International
Health Systems is on pace this year for nearly $50 million in revenue, up from $42 million last year and just $4.5 million eight years ago. The Indianapolis company processes claims for health insurers when patients receive out-of-network care.
Rival’s strong results have WellPoint playing catch-up
UnitedHealth has been enjoying healthy profits, growing customer rolls and a rising stock price—things the Indianapolis insurer has been unable to match. That tough comparison lies behind some of the investor attacks on WellPoint CEO Angela Braly.
Mayor signs off on domestic-partner ordinance
The ordinance covering city employees offers insurance coverage to both same-sex and heterosexual unmarried couples. The mayor also signed the “Complete Streets” proposal.